Latham & Watkins Advises Underwriters in Gilead Sciences’ US$7.25 Billion Senior Unsecured Notes Offering

Bicoastal deal team represented the underwriters in the offering by the biopharmaceutical company.

September 28, 2020

Gilead Sciences, Inc. has announced the pricing of senior unsecured notes in an aggregate principal amount of US$7.25 billion, in an underwritten, registered public offering, consisting of seven tranches. The offering is expected to close September 30, 2020, subject to customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Greg Rodgers and Orange County partner Shayne Kennedy, with New York associates Taylor Stevens and Patrick Maguire. Advice was also provided on finance matters by New York partner Melissa Alwang, with New York associates Joseph Zenruffinen and Angelika Ishkhanyan; on tax matters by New York partner Bora Bozkurt, with New York associate Michael Yu; on intellectual property matters by New York partner Alan Tamarelli; on FDA regulatory matters by Washington, D.C. counsel Carolyne Hathaway, with San Diego/Washington, D.C. associate Amy Speros and New York associate Lacey Henry; on healthcare regulatory matters by Bay Area counsel Betty Pang; and on OFAC/AML matters by Washington, D.C. partner Eric Volkman, with Washington, D.C. associate Jason Despain.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.